Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson’s Disease

[Image: see text] Parkinson’s disease (PD) is a debilitating and common neurodegenerative disease. New insights implicating c-Abl activation as a driving force in PD have opened a new drug development avenue for PD treatment beyond the symptomatic relief by L-DOPA. BCR-Abl inhibitors, which include...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ACS Med Chem Lett
Hlavní autoři: Kaiser, Thomas M., Dentmon, Zackery W., Dalloul, Christopher E., Sharma, Savita K., Liotta, Dennis C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Chemical Society 2020
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7153011/
https://ncbi.nlm.nih.gov/pubmed/32292555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00612
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky